Financial Performance - Q3 2025 - Revenue increased by 74% year-over-year to $5415 million, or 65% in constant currency[5] - GAAP diluted EPS was $056, while adjusted diluted EPS reached $139[6] - GAAP operating margin was 160%, matching the adjusted operating margin[8] Cash Flow - Operating cash flow surged to $1227 million, compared to $847 million in Q3 2024[6] - Free cash flow also increased significantly to $1160 million from $791 million in the same period last year[6] Revenue Breakdown - Q3 2025 - Products & Resources segment revenue was $1383 million, a 126% year-over-year increase, or 114% in constant currency[17] - Health Sciences revenue reached $1604 million, up 59% year-over-year, or 51% in constant currency[17] - Financial Services revenue was $1578 million, reflecting a 62% year-over-year increase, or 54% in constant currency[17] - Communications, Media & Technology revenue totaled $850 million, a 42% year-over-year increase, or 36% in constant currency[17] Bookings and Employee Metrics - Trailing twelve-month bookings increased by 5% year-over-year to $275 billion, resulting in a book-to-bill ratio of 13x[39, 40] - Headcount increased to 3498 thousand[42] Guidance - Full-year 2025 revenue is projected to be between $2105 billion and $2110 billion, representing a 66% to 69% year-over-year increase, or 60% to 63% in constant currency[46] - Adjusted diluted EPS for the full year is expected to be in the range of $522 to $526[46]

Third Quarter 2025 Earnings Disclaimer Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, statements relating to driving organic and inorganic growth, and 2025 Adjusted EBITDA outlook. Some of the forward-looking statements can be identified by the use of terms such as "may," "intend," "might," "will," "should," "could," "would," "expect, ...

Financial Performance & Guidance - CVS Health delivered consolidated revenue growth of 7.8% in the third quarter of 2025 [6] - Adjusted EPS for the third quarter of 2025 was $1.60 [6, 7] - The company raised its 2025 adjusted EPS guidance to a range of $6.55 to $6.65 [6, 19] - CVS Health anticipates at least $397.3 billion in consolidated revenue for full year 2025 [8] - Full year 2025 cash flow from operations is projected to be between $7.5 billion and $8.0 billion [8] Segment Performance - Health Care Benefits total revenues for 3Q 2025 were $36.0 billion [24] - Health Services total revenues for 3Q 2025 were $49.3 billion [27] - Pharmacy & Consumer Wellness total revenues for 3Q 2025 were $36.2 billion [31] - Same store pharmacy sales increased by approximately 16.8% and same store prescription volumes increased by approximately 8.9% [32] - Retail pharmacy script share reached approximately 28.9% [32]

Q3 2025 Financial Performance - Net Revenues reached $931 million[16] - Adjusted EBITDA was $168 million[16] - Adjusted EBITDA margin was 18%[16] Segment Performance (Q3 2025) - Reynolds Cooking & Baking: Net Revenues of $308 million, Adjusted EBITDA of $53 million, with a 17% margin[16] - Hefty Waste & Storage: Net Revenues of $266 million, Adjusted EBITDA of $74 million, with a 28% margin[16] - Hefty Tableware: Net Revenues of $200 million, Adjusted EBITDA of $29 million, with a 15% margin[16] - Presto Products: Net Revenues of $163 million, Adjusted EBITDA of $35 million, with a 21% margin[16] Year-to-Date (YTD) 2025 Financials - Net Revenues totaled $2,687 million[18] - Adjusted EBITDA amounted to $447 million[18] - Adjusted EBITDA margin was 17%[18] Q4 2025 Outlook - Net Revenues are expected to decrease by 1% to 5%[21] - Net Income is projected to be between $110 million and $118 million[21] - Adjusted EBITDA is forecasted to be between $208 million and $218 million[21] Full Year 2025 Outlook - Net Revenues are expected to be flat to down 1%[22] - Net Income is projected to be between $294 million and $302 million[22] - Adjusted EBITDA is forecasted to be between $655 million and $665 million[22]

Third Quarter 2025 October 29, 2025 EARNINGS CONFERENCE CALL © 2024 Forward-Looking Statements & Non-GAAP Disclaimer Forward-Looking Statements This presentation includes forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning the Company's plans, goals, objectives, outlook, expectations, and intentions, including statements that are ...

Financial Performance - The company's Normalized Adjusted EPS was $1.05 in 3Q 2025[3], compared to $1.53 in 2Q 2025, a decrease of 31%[13] - Adjusted Net Trading Income (NTI) reached $467 million in 3Q 2025[3], a 20% decrease from $568 million in 2Q 2025 but a 21% increase from $388 million in 3Q 2024[13] - Daily Average Adjusted NTI was $7.4 million in 3Q 2025[3] - Adjusted EBITDA was $268 million in 3Q 2025, with an Adjusted EBITDA Margin of 57%[3] - The company's Debt to Last Twelve Months (LTM) Adjusted EBITDA ratio stood at 1.7x[3] - LTM 3Q'25 Normalized Adjusted EPS was $5.01 and LTM 3Q'25 Adjusted NTI/day was $8.0 million[4] Business Segments - Market Making Adjusted NTI was $344 million in 3Q 2025, representing 74% of the total Adjusted NTI[13] - Execution Services Adjusted NTI was $123 million in 3Q 2025, accounting for 26% of the total Adjusted NTI[13] - VES Adjusted NTI has increased in 6 consecutive quarters (+32% vs 1Q 2024)[4] Market Metrics - US Equity Consolidated Notional Volume averaged $827 billion daily in 3Q 2025, a 3% increase compared to 2Q 2025 and a 41% increase compared to 3Q 2024[15] - Virtu Rule 605 Executed Shares averaged 800 million in 3Q 2025, a 7% increase compared to 2Q 2025 and a 45% increase compared to 3Q 2024[15]

Third Quarter 2025 Financial Results October 29, 2025 © 2025 Fiserv, Inc. or its affiliates Forward-Looking Statements and Non-GAAP Financial Measures Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding anticipated organic revenue growth, adjusted earnings per share, adjusted earnings per share growth, free cash flow, adjusted operating margin expansion, and other statement ...

Q3 2025 Earnings Investor Presentation Safe Harbor Statement This presentation contrains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 2IE of the Securities Exchange Act of 1934, as amended, that are based on our management's beliefs and assumptions and on information currently available to them. All stotements other than present and historical facts and conditions contained in this presentation, including statements regarding our possi ...

29 October 2025 Q3 2025 Results Conference call and webcast for investors and analysts gsk.com Agenda Q3 2025 strong performance improves further Emma Walmsley Performance: growth drivers 2 Cautionary statement regarding forward-looking statements Luke Miels and Deborah Waterhouse Q3 2025 financial performance Julie Brown Summary and Q&A Emma Walmsley, Luke Miels, Deborah Waterhouse, Julie Brown, Tony Wood and David Redfern This presentation may contain forward-looking statements. Forward-looking statements ...

Interim Data for KYSA-6 Phase 2 Clinical Trial of KYV-101 in Generalized Myasthenia Gravis Conference Call October 29, 2025 Cindy MG Warrior Disclaimer and Forward-Looking Statements This presentation contains forward-looking statements that are based on management's beliefs and assumptions and information currently available to management of Kyverna Therapeutics, Inc. ("Kyverna", "we", "our," or the "Company"). All statements other than statements of historical facts contained in this presentation are forw ...